Navigation Links
Oncology basic research director at John Theurer Cancer Center continues transplantation research
Date:1/18/2011

HACKENSACK, N.J. (December XX, 2010) Thea Friedman, M.D., associate scientist and director of oncology basic research at the John Theurer Cancer Center at Hackensack University Medical Center was recently awarded a National Cancer Institutes of Health-National Cancer Institute (NIH-NCI) RO1 research grant to improve allogeneic blood and marrow transplantation for multiple myeloma patients. The grant provides $2 million in funding over the next five years.

As part of the John Theurer Cancer Center's continued efforts to improve outcomes of blood and marrow transplantation, Dr. Friedman and her colleagues have been using a molecular technique called T cell receptor Vβ CDR3 spectratype analysis to look at T-cell repertoires for the purpose of separating the donor cells responsible for graft-versus-host disease from those mediating graft-versus-tumor responses. Once separated, Dr. Friedman and her team will come closer to "personalized" transplantation, a huge milestone for the multiple myeloma community.

"This significant funding provided by the NIH is instrumental to further our blood and marrow transplant research," said Dr. Friedman. "We look forward to the possibility of using personalized transplantation to better the lives of cancer patients in our community and around the world."

The ROI research is the original and oldest grant mechanism used by NIH. The RO1 applications are peer reviewed and only those scoring above the 15th percentile are awarded. Last year, only 25 percent of the 50,000 applications were awarded a grant.

"The John Theurer Cancer Center constantly strives to provide the medical community with the latest advancements and innovations in oncology," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovations officer and professor and vice president of cancer services, the John Theurer Cancer Center. "Dr. Friedman and her colleagues' research is just one example of our commitment to advance innovative and treatment options in this fight against cancer."

Dr. Friedman first began this body of research in 2000 when she received a grant award from the National Marrow Donor Program. She applied for her first RO1 grant, which she was awarded in July 2003.

Dr. Friedman and her team plan to move their transplant research into a Phase I clinical trial in late 2011. Collaborators from the John Theurer Cancer Center include Robert Korngold, Ph.D., chief of oncology basic research; Scott Rowley, M.D., co-chief of blood and bone marrow stem cell & transplantation; David Siegel, M.D., Ph.D., chief of multiple myeloma and Michele Donato, M.D., collection facility medical director, blood & marrow transplantation.

In January 2011, the John Theurer Cancer Center's team of expert physicians, researchers and staff will begin transitioning into a new, $130-million comprehensive care facility. The new facility is equipped with a dedicated Phase 1 unit, tumor banking, new modalities of delivery of radiation and future molecular imaging technology to further support the development of innovative therapies and approaches to improve patient outcomes.


'/>"/>

Contact: Jaymie DeGaetano
jaymie.degaetano@widmeyer.com
646-213-7243
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. European Multidisciplinary Conference in Thoracic Oncology
2. Spanish Oncology to establish a new standard treatment on breast cancer at early stages
3. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
4. OncologyPRO: Unique portal for cancer specialists
5. Boston, Oct. 21-24: Largest international pediatric oncology conference
6. Grant will aid creation of interdisciplinary oncology palliative care education program
7. Elsevier and International Society of Geriatric Oncology launch Journal of Geriatric Oncology
8. Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways
9. Space Coast Cancer Center Selects Via Oncology™ Pathways to Advance Evidence-Based Cancer Care
10. Peace of Mind Skin Care Announces new Services in Oncology Esthetics
11. Christiana Care Health Systems Darcy Burbage Receives Oncology Nursing Society Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO ... year. Dyer started as the Chairman of the Management Committee when IFN was ... corporation including the recruitment of investor/owners and development of the business plan. He ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... announced an official 2017 partnership with The Jensie Gran Fondo of Marin. For ... and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... -- Physician General Dr. Rachel Levine and ... Smith commended South Central EMS today for their ... a life-saving overdose reversal drug. The recognition event also ... overdose survivor who was saved due to the administration ... part of fighting the opioid epidemic is making sure ...
(Date:2/24/2017)... 2017 Report analyzes the worldwide markets for Endodontic ... for the US, Canada , ... Asia-Pacific , Latin America , and ... the period 2015 through 2022. Also, a six-year historic analysis ... derived from primary and secondary research. Company profiles are primarily ...
(Date:2/24/2017)... Feb. 23, 2017 Non-alcoholic steatohepataitis ... the various drugs being developed for the ... the drugs that are in various phases ... pipeline focuses on novel pharmacologic drugs & ... cell therapies, recombinant proteins and RNA-based therapeutics, ...
Breaking Medicine Technology: